TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
申请人:Arvinas, Inc.
公开号:US20180125821A1
公开(公告)日:2018-05-10
The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
various spacers to furnish a series of bifunctionallinkers. One linker (7a) has been used for the construction of a biosensor for β-lactam antibiotic detection by attenuatedtotalreflectanceFTIR (ATR-FTIR) spectroscopy. Linkers featuring a photosensitive aryl azide motif at one end and a function reactive toward nucleophiles at the other end are described. One linker is used for the construction of a
申请人:UPPTHERA, INC. (주) 업테라(120190426454) Corp. No ▼ 120111-0948185BRN ▼179-87-01005
公开号:KR102160377B1
公开(公告)日:2020-09-28
본 발명은 HMG-CoA 환원효소 분해 유도 화합물에 관한 것이다. 구체적으로, 본 발명은 HMG-CoA 환원효소 결합 모이어티로서 아토르바스타틴 및 E3 유비퀴틴 라이게이즈 결합 모이어티가 화학적 링커로 연결된 이기능성 화합물, 이의 제조방법, 이를 이용한 HMG-CoA 환원효소의 분해 방법, 및 이를 포함하는 HMG-CoA 환원효소 관련 질환의 예방 또는 치료용 약학 조성물에 관한 것이다.
[EN] HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND<br/>[FR] COMPOSÉ INDUISANT LA DÉGRADATION DE LA HMG-COA RÉDUCTASE
申请人:UPPTHERA
公开号:WO2021201577A1
公开(公告)日:2021-10-07
The present invention relates HMG-CoA reductase degradation inducing compounds. Specifically, the present invention relates a bifunctional compound in which a HMG-CoA reductase binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention also relates a method for preparing the compounds, and a method for degradation of HMG-CoA reducatase using the compounds, as well as use for prevention or treatment of HMG-CoA reductase related diseases using the compounds.